[1]Lai CL, Gane E, Liaw YF, et al.Telbivudine versus lamivudinein patients with chronic hepatitis B[J].N EngI J Med, 2007, 357 (25) :2576-2588.
|
[2]Yuen MF, Lai CL.Telbivudine for chronic hepatitis B:theGLOBE trial[J].Future Virol, 2008, 3 (4) :317-323.
|
[3]Liaw YF.On-treatment outcome prediction and adjustmentduring chronic hepatitis B therapy:now and future[J].AntivirTher, 2009, 14 (10) :13-22.
|
[4]Keeffe EB, Dieterich DT, Han SH, et al.A treatment algorithmfor the management of chronic hepatitis B virus infectionin the United States:2008 update[J].Clin GastroenterolHepatol, 2008, 6 (12) :1315-1341.
|
[5]Chinese Society of Hepatology of Chinese MedicalAssociation, Chinese Society of Infectious Diseases ofChinese Medical Association.The guideline of preventionand treatment for chronic hepatitis B (2010 version) [J].Zhongguo Bingdubing Zazhi, 2011, 19 (1) :13-24.
|
[6]European Association for the Study of the Liver.EASL clinicalpractice guidelines:management of chronic hepatitis B[J].JHepatol, 2009, 50 (2) :227-242.
|
[7]Chae HB, Hann HW.Baseline HBV DNA levels is the mostimportant factor associated with virology breakthroughin chronic hepatitis B treated with lamivudine[J].World JGastroenterol, 2007, 13 (30) :4085-4090.
|
[8]Liaw YF, Gane E, Leung N, et al.2-year GLOBE trial results:telbivudine is superior to lamivudine in patients with chronichepatitis B[J].Gastroenterology, 2009, 136 (2) :486-495.
|
[9]Zeuzem S, Gane E, Liaw YF, et al.Baseline characteristicsand early on-treatment response predict the outcomes of2 years of telbivudine treatment of chronic hepatitis B[J].JHepatol, 2009, 51 (1) :11-20.
|
[10]Gauthier J, Bourne M, Lutz MW, et al.Quantization of hepatitis viremia and emergence of YMDD variants in patientswith chronic hepatitis B treated with lamivudine[J].J InfectDis, 1999, 180 (6) :1757-1762.
|
[11]Gallego A, Sheldon J, Garcia-Samaniego J, et al.Evaluationof initial virological response to adefovir and development ofadefovir-resistant mutations in patients with chronic hepatitisB[J].J Viral Hepat, 2008, 15 (5) :392-398.
|
[12]Yuen MF.On-treatment outcome prediction and adjustmentduring chronic hepatitis B threapy:now and future[J].Antiviral Ther, 2009, 14 (1) :13-22.
|
[13]Hsu CW, Chen YC, Liaw YF, et al.Prolonged efficacy andsafety of 3 years of continuous telbivudine treatment inpooled data from GLOBE and 015 study in chronic hepatitisB patients[J].J Hepatol, 2009, 50 (Suppl 1) :S331.
|
[14]Jia JD, Gane E.Prolonged efficacy and safety of 4 yearscontinuous telbivudine treatment in chronic hepatitis B (CHB) patients from GLOBE and 015 studies[J].Hepatol Int, 2010, 4 (Suppl 1) :56.FP 090.
|
[15]Yuen MF, Fung J, Seto WK, et al.Combination of baselineparameters and on-treatment hepatitis B virus DNA levels tostart and continue patients with lamivudine therapy[J].AntivirTher, 2009, 14 (5) :679-685.
|
[16]Chinese Telbivudine Roadmap Expert Group.Chineseroadmap for management of chronic hepatitis B patientsreceiving Telbivudine treatment[J].Zhonghua ChuanranbingZazhi, 2008, 26 (5) :257-259.
|
[17]Dong N, He B, Zhuang H.An online questionnaire surveyon awareness of antiviral treatment in patients with chronichepatitis B[J].Ganzang, 2009, 14 (1) :8-10.
|
[18]Wang L, Liu F, Liu YD, et al.Stringent cessation criterionresults in better durability of lamivudine treatment:aprospective clinical study in hepatitis B e antigen-positivechronic hepatitis B patients[J].J Viral Hepat, 2010, 17 (4) :298-304.
|
[19]Cai W, Xie Q, An BY, et al.On-treatment serum HBsAg levelis predictive of sustained off-treatment virologic responseto telbivudine in HBeAg-positive chronic hepatitis Bpatients[J].J Clin Virol, 2010, 48 (1) :22-26.
|